• Company achieved ₹1,150 crore revenue in 9M FY26 with EBITDA of ₹153 crores, representing 32% YoY growth
• PAT reached ₹75 crores compared to ₹59.6 crores last year, despite ₹4.5 crore exceptional provision for new labor law
• Successfully commercialized 12 out of 102 granted patents, with patented products contributing 20% of total revenues at 55-60% gross margins (versus 35-40% for generics)
• Launched blockbuster seed treatment product PCT-410 which scaled to ₹50-70 crore revenue in just 2-3 years
• Established subsidiary in Brazil for international expansion and began registering patented products in new geographies
• Built extensive distribution network of 5,000 distributors across India through 24 C&F locations reaching three states
• Operates integrated manufacturing with technical plant utilization at 70-75% and formulation at 30-40% due to seasonality
• Partnered with major co-marketing partners including Rallis, Sumitomo Chemicals, Mankind Pharma, and Chambal Fertilizers for white-label patented products

GSP Crop Science demonstrated strong Q3 FY26 performance with 32% EBITDA growth and PAT of ₹75 crores despite challenging monsoon conditions. The company's differentiated strategy of launching patented combination products (102 patents granted, 108 in pipeline) with 20% higher margins than generics is gaining traction, contributing 20% of revenues. Management expects to maintain growth momentum through innovative product launches and geographic expansion into Brazil.

GSP Crop Science reported revenues of ₹1,150 crores for the nine months ended December 2025, with formulation revenues at ₹1,114 crores. EBITDA reached ₹153 crores, marking a 32% increase year-over-year. PAT stood at ₹75 crores versus ₹59.6 crores last year, representing 26% growth even after absorbing ₹4.5 crore in exceptional provisions related to new labor law compliance. The business mix comprises 40% domestic B2B, 40% domestic B2C (totaling 80% domestic), and 20% exports to 37 countries. Patented products now contribute approximately 20% of revenues with gross margins of 55-60% compared to 35-40% for generic products, providing a 20-25% premium. The company maintains 75% of business from formulations and 25% from technical products, with technical plant capacity utilization at 70-75%.

Management displayed strong confidence in their differentiation strategy centered on innovation and patents. Chairman Bhavish Shah emphasized the company's 40-year legacy and highlighted their R&D capabilities with two dedicated facilities for technical and formulation development. The strategic focus on launching first-in-India products (10 launched over 15 years) and developing patentable novel combinations demonstrates long-term vision. CFO's discussion emphasized successful price pass-through in B2B business and co-marketing partnerships with major players validating their products. Management expects existing capacity with debottlenecking to support three years of growth, targeting one to two new patented product launches annually. They projected maintaining or exceeding current growth rates with an additional 7% acceleration over the next three years, showing confidence despite monsoon challenges and geopolitical uncertainties.

The company faces several headwinds including lower monsoon forecast affecting overall agricultural demand, though management noted their paddy crop focus (40% of business) in irrigated areas provides some insulation. Raw material costs have increased significantly due to crude oil price escalation from Middle East conflicts, with logistics costs from China doubling due to shipping constraints. While B2B price increases have been successfully implemented (approximately 15%), B2C channel pricing faces lag and competitive pressures making cost pass-through more difficult. Supply chain risks exist with heavy dependence on Chinese intermediates and raw materials, with management warning that prolonged disruption beyond one more month could impact production despite current inventory buffers. Fertilizer shortages are affecting farmer purchasing power. Technical plant capacity utilization at 70-75% suggests limited room for volume expansion without capital investment. The five-year registration timeline for new patented products creates significant time-to-market delays.

Revenue Outlook: Management expects to maintain current growth trajectory with an additional 7% acceleration over next three years; existing capacity sufficient for three-year growth strategy

Margin Outlook: Patented products expected to increase from 20% to 40-50% of revenue mix in three years, implying significant margin expansion given 20-25% premium over generics

Key Targets:

• Launch 1-2 new patented products annually
• Increase patented product contribution from 20% to 40-50% of revenues in three years
• Expand geographic presence with Brazil subsidiary operational
• Register and commercialize patented products in international markets
• Continue first-in-India technical product launches

The Q&A session focused heavily on three key themes: (1) supply chain risks and cost inflation management, with analysts probing China dependency and Middle East conflict impacts; (2) the differentiation strategy around patented products, with detailed questions on commercialization rates, margins, and growth trajectory; and (3) capacity utilization and capital requirements for growth. Analysts showed particular interest in understanding the sustainability of margin expansion given raw material headwinds and competitive dynamics. Management responded confidently, emphasizing successful price pass-through in B2B (though acknowledging B2C challenges), strong validation through co-marketing partnerships, and adequate capacity runway. The tone was generally positive with management demonstrating command of details around product launches, partner relationships, and capacity planning. However, some caution was evident regarding monsoon impacts and supply chain vulnerabilities, with management providing specific risk parameters (e.g., one-month buffer on China supplies). Overall, analysts appeared satisfied with the innovation-driven growth strategy but remained focused on execution risks around supply chain, capacity constraints, and the long development timelines for new products.